Search Swinburne Research Bank
Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.3/227521
- Developing a nontypeable Haemophilus influenzae (NTHi) vaccine
- Poolman, J. T.; Bakaletz, L.; Cripps, A.; Denoel, P. A.; Forsgren, A.; Kyd, J.; Lobet, Y.
- There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, ...) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.
- Publication type
- Journal article
- Vaccine, Vol. 19, supplement 1 (Dec 2000), pp. S108-S115
- Publication year
- FOR Code(s)
- 06 Biological Sciences; 07 Agricultural and Veterinary Sciences; 11 Medical and Health Sciences
- Animal models; Haemophilus influenzae; LPD; LB1/fimbrin/P5; NTHi; OMP26; Otitis; Vaccine research
- Publisher URL
- Copyright © 2000 Elsevier Science Ltd. All rights reserved.
- Peer reviewed